ClinicalTrials.gg

Program

HRS-2329

A development code. Also written as “HRS-2329 Tablet”.

Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Sep 17, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 1since Sep 17, 2025Sep 17, 2025Dec 2028phase 1 · NCT07189949
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-2329, phase 1, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2025First study: phase 1 study in Advanced Solid Tumors Harboring RAS Mutations or AmplificationsFirst studyNCT07189949 · 120 planned · China

Ahead

  1. Dec 2028Primary completion: phase 1 study in Advanced Solid Tumors Harboring RAS Mutations or AmplificationsNCT07189949

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07189949Advanced Solid Tumors Harboring RAS Mutations or Amplifications · China1RecruitingDec 2028120

How it is read

Names in the registry

  • “HRS-2329 Tablet”, 1 entry

Codes read as this program: HRS2329.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.